Sage Therpeutics Says Primary Efficacy And Safety Endpoints Met In Phase 1/2 Trial Of SAGE-547 In Super-Refractory Status Epilepticus
November 11, 2014 at 06:35 AM EST
BZ NOTE: From Sage Filing: Top-line data reported from12 patients enrolled in the trial show that all 12 patients ...
